BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30059212)

  • 1. Synthesis and Activity of a Novel Autotaxin Inhibitor-Icodextrin Conjugate.
    Fisher N; Edwards MG; Hemming R; Allin SM; Wallis JD; Bulman Page PC; Mckenzie MJ; Jones SM; Elsegood MRJ; King-Underwood J; Richardson A
    J Med Chem; 2018 Sep; 61(17):7942-7951. PubMed ID: 30059212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendrimer Conjugate of [4-(Tetradecanoylamino)benzyl]phosphonic Acid (S32826) as an Autotaxin Inhibitor.
    Fisher N; Hilton-Bolt T; Edwards MG; Haxton KJ; McKenzie M; Allin SM; Richardson A
    ACS Med Chem Lett; 2014 Jan; 5(1):34-9. PubMed ID: 24900771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
    Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
    Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of novel 2-pyrrolidinone and pyrrolidine derivatives and study of their inhibitory activity against autotaxin enzyme.
    Gerokonstantis DT; Nikolaou A; Magkrioti C; Afantitis A; Aidinis V; Kokotos G; Moutevelis-Minakakis P
    Bioorg Med Chem; 2020 Jan; 28(2):115216. PubMed ID: 31864778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
    Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
    J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, and Preliminary Bioactivity Evaluation of 2,7-Substituted Carbazole Derivatives as Potent Autotaxin Inhibitors and Antitumor Agents†.
    Wang W; Zhao F; Zhao Y; Pan W; Cao P; Wu L; Wang Z; Zhao X; Zhao Y; Wang H
    Anticancer Agents Med Chem; 2019; 19(2):256-264. PubMed ID: 30173652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.
    Thirunavukkarasu K; Tan B; Swearingen CA; Rocha G; Bui HH; McCann DJ; Jones SB; Norman BH; Pfeifer LA; Saha JK
    J Pharmacol Exp Ther; 2016 Oct; 359(1):207-14. PubMed ID: 27516465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo.
    Reich R; Hoffman A; Suresh RR; Shai O; Frant J; Maresca A; Supuran CT; Breuer E
    J Enzyme Inhib Med Chem; 2015; 30(5):767-72. PubMed ID: 25669348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.
    Ayyagari VN; Johnston NA; Brard L
    Anticancer Drugs; 2016 Jul; 27(6):547-59. PubMed ID: 27058706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
    Thirunavukkarasu K; Swearingen CA; Oskins JL; Lin C; Bui HH; Jones SB; Pfeifer LA; Norman BH; Mitchell PG; Chambers MG
    Osteoarthritis Cartilage; 2017 Jun; 25(6):935-942. PubMed ID: 27638130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension.
    Saga H; Ohhata A; Hayashi A; Katoh M; Maeda T; Mizuno H; Takada Y; Komichi Y; Ota H; Matsumura N; Shibaya M; Sugiyama T; Nakade S; Kishikawa K
    PLoS One; 2014; 9(4):e93230. PubMed ID: 24747415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rhodium(III)-based inhibitor of autotaxin with antiproliferative activity.
    Kang TS; Wang W; Zhong HJ; Liang JX; Ko CN; Lu JJ; Chen XP; Ma DL; Leung CH
    Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):256-263. PubMed ID: 27888146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
    Ragle LE; Palanisamy DJ; Joe MJ; Stein RS; Norman DD; Tigyi G; Baker DL; Parrill AL
    Bioorg Med Chem; 2016 Oct; 24(19):4660-4674. PubMed ID: 27544588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of a pipemidic acid autotaxin inhibitor.
    Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
    J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autotaxin inhibition: development and application of computational tools to identify site-selective lead compounds.
    Norman DD; Ibezim A; Scott WE; White S; Parrill AL; Baker DL
    Bioorg Med Chem; 2013 Sep; 21(17):5548-60. PubMed ID: 23816044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors.
    Jing T; Miao X; Jiang F; Guo M; Xing L; Zhang J; Zuo D; Lei H; Zhai X
    Bioorg Med Chem; 2018 May; 26(8):1784-1796. PubMed ID: 29496411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer.
    Barbayianni E; Kaffe E; Aidinis V; Kokotos G
    Prog Lipid Res; 2015 Apr; 58():76-96. PubMed ID: 25704398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode.
    Miller LM; Keune WJ; Castagna D; Young LC; Duffy EL; Potjewyd F; Salgado-Polo F; Engel García P; Semaan D; Pritchard JM; Perrakis A; Macdonald SJ; Jamieson C; Watson AJ
    J Med Chem; 2017 Jan; 60(2):722-748. PubMed ID: 27982588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
    Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
    J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of metastasis of intravenously-inoculated B16/F10 melanoma cells by the novel ginseng-derived ingredient, gintonin: involvement of autotaxin inhibition.
    Hwang SH; Lee BH; Kim HJ; Cho HJ; Shin HC; Im KS; Choi SH; Shin TJ; Lee SM; Nam SW; Kim HC; Rhim H; Nah SY
    Int J Oncol; 2013 Jan; 42(1):317-26. PubMed ID: 23174888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.